



PEI Pharmacare  
P.O. Box 2000  
Charlottetown, PE  
C1A 7N8  
www.princeedwardisland.ca



Programmes provinciaux de médicaments  
C.P. 2000  
Charlottetown, PE  
C1A 7N8  
www.princeedwardisland.ca

# PEI Pharmacare Bulletin

**Issue (2025-06) March 11, 2025**

**NEW PRODUCT(S) ADDED TO THE PEI PHARMACARE FORMULARY**  
**(EFFECTIVE DATE: MARCH 25, 2025)**

Product (Generic name)	Product (Brand name)	Strength	Dosage Form	DIN	MFR
------------------------	----------------------	----------	-------------	-----	-----

<b>Alirocumab</b>	<b>Praluent</b>	<b>300mg/2mL</b>	<b>Pre-filled pen</b>	<b>02547732</b>	<b>SAV</b>
Criteria	See online Formulary for Alirocumab criteria.				
Program Eligibility	Family Health Benefit Drug Program, Financial Assistance Drug Program, Nursing Home Drug Program, Catastrophic Drug Program, Seniors Drug Program				

<b>Cysteamine</b>	<b>Cystadrops</b>	<b>3.8 mg/mL</b>	<b>Vial</b>	<b>02485605</b>	<b>RRD</b>
Criteria	For the treatment of corneal cystine crystal deposits (CCCDs) in patients 2 years of age and older with cystinosis.				
	Clinical Note: <ul style="list-style-type: none"> <li>Diagnosis of cystinosis confirmed by cystinosis (lysosomal cystine transporter) gene mutation or elevated white blood cell cystine levels. Documentation must be provided.</li> </ul>				
	Claim Note: <ul style="list-style-type: none"> <li>Must be prescribed by an ophthalmologist experienced in the treatment of CCCDs.</li> </ul>				
Program Eligibility	Financial Assistance Drug Program, High Cost Drug Program, Nursing Home Drug Program, Catastrophic Drug Program				